

# SkinBioTherapeutics PLC

09:00 01 May 2019

## SkinBioTherapeutics makes progress with SkinBiotix platform

- Life sciences company focused on skin health
- Uses lysates of probiotic bacteria to increase skin integrity
- Efficacy shown in first human study of SkinBiotix cream What SkinBioTherapeutics does

SkinBioTherapeutics PLC (LON:SBTX) is a life sciences company that focuses on the health of the skin through its proprietary platform technology SkinBiotix.

The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance.

The company is currently targeting three main skincare sectors; cosmetics, infection control and eczema, with its most advanced research programme currently focused on using the SkinBiotix platform in cosmetics to manage sensitive skin.

### Inflexion points

- In mid-April, the company appointed Stuart John Ashman, the former sales and marketing director of wound care, casting and bandaging at FTSE 100-listed Smith & Nephew, to the board having previously designated him as the successor to CEO Dr Cath O'Neill in March
- Data from the first human study of the company's SkinBiotix cream revealed that the product was well tolerated and efficacious in certain age groups and at certain time points, with the under 50s group seeing a statistically significant increase in skin hydration at day 15. There was also a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort
- In February, the company raised £1.5m by selling shares to existing investor Seneca Partners, taking the investment manager's holding in SkinBio to 20.9% from 14.6%

### Blue Sky

With Ashman scheduled to take over the CEO role, O'Neill going forward will be focusing on the scientific development of the SkinBiotix platform as well as the firm's ongoing commercial discussions.

"Stuart's appointment as a director adds further commercial capability to the board. He has a considerable network within the medtech and life science industries and the experience and drive to take us forward on the next stage of the company's development," said Martin Hunt, the company's non-executive chairman.


Ashman himself said that upon appointment his immediate focus would be for the company to "continue to support the clinical development of the technology whilst building on the ongoing commercial discussions."

Regarding the results of the company's first human trial, O'Neill says that the data will form "a launch pad" for talking to

**Price:** 18.12

**Market Cap:** £23.21 m

### 1 Year Share Price Graph



November 2018 May 2019 November 20

### Share Information

**Code:** SBTX

**Listing:** AIM

**52 week High Low**  
 26 12

**Sector:** Pharma & Biotech

**Website:** [www.skinbiotherapeutics.com](http://www.skinbiotherapeutics.com)

### Company Synopsis:

*SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

potential licensees for the SkinBiotix formula.

"Our potential [commercial] partners have said that provided the technology is safe...everything else can be sorted out by formulation."

"We already knew it was safe because there have been no adverse effects reported...but to show efficacy on top of that is stellar".

O'Neill added that following the data there was "a lot of scope" for the company to further optimise the formulation of the cream to make it more suitable for different age groups.

With shares trading at around 15.3p as of 1 May, SkinBioTherapeutics has a market cap of £20.49mln.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).